<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375241</url>
  </required_header>
  <id_info>
    <org_study_id>9275</org_study_id>
    <nct_id>NCT04375241</nct_id>
  </id_info>
  <brief_title>Detection of Asymptomatic Atrial Fibrillation in Persons of 65 Year of Age or Older</brief_title>
  <acronym>DETECT AF</acronym>
  <official_title>Detection of Asymptomatic Atrial Fibrillation in Persons of 65 Year of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diagram B.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diagram B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although the condition itself
      is not life-threatening, the complications result in increased morbidity and mortality. AF is
      often asymptomatic and a considerable number of people suffering from AF are not aware of
      their condition. Unfortunately, a cerebral infarction is often the first clinical
      manifestation. The idea to screen subjects opportunistically for Asymptomatic Atrial
      Fibrillation (AAF) was infeasible until recently. However, with a recently-developed
      smartphone connected Mobile ECG Device (MED), this seems to be feasible after all.

      The main objectives are:

        -  To examine the feasibility of screening subjects of ≥65 years old for AAF.

        -  To validate the smartphone connected MED as an AAF screening instrument for application
           in transmural care in the Netherlands.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      Prospective validation study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Sensitivity of the mobile ECG device</measure>
    <time_frame>At screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the mobile ECG device</measure>
    <time_frame>At screening</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Screening with Mobile ECG Device</arm_group_label>
    <description>Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device</intervention_name>
    <description>Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device</description>
    <arm_group_label>Screening with Mobile ECG Device</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participants of this study will be subjects who visit their general practicioner or
        cardiologist or who visit the DETECT AF team at an event.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥65 years

          -  Is willing to give informed consent

        Exclusion Criteria:

          -  Known medical history with Atrial Fibrillation

          -  Not mental competent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. A. Elvan, MD, PhD</last_name>
    <phone>+31 384243234</phone>
    <email>a.elvan@isala.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>S. Postma, PhD</last_name>
    <phone>+31 384262999</phone>
    <email>s.postma@diagram-zwolle.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. A Elvan, MD, PhD</last_name>
      <phone>+31 384243234</phone>
      <email>a.elvan@isala.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mobile ECG device</keyword>
  <keyword>Asymptomatic atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We have not yet decided to share the individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

